
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc's current valuation is deemed attractive, indicating significant upside potential based on a net present value (NPV) analysis. The company's lead product candidate, oral (Z)-endoxifen, is in Phase 2 clinical development, with the potential to achieve key clinical milestones that could act as strong catalysts for stock performance. Furthermore, Atossa Therapeutics is making notable progress in its ongoing clinical trials, which enhances the outlook regarding its growth prospects and value in the oncology market.
Bears say
Atossa Therapeutics reported a net loss of $10.9 million, translating to an earnings per share (EPS) of $(1.27), which fell short of expectations compared to previous estimates. The company is facing significant financial challenges, including liquidity risks and the potential failure of its lead product candidate to prove safety and efficacy in ongoing clinical trials. Additionally, the firm confronts hurdles related to regulatory approvals, commercialization capabilities, reimbursement issues, and increasing competition, all of which contribute to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares